Literature DB >> 34750558

CDK4/6 inhibitors in breast cancer: spotting the difference.

Jose Manuel Perez-Garcia1,2,3, Javier Cortes4,5,6,7,8, Antonio Llombart-Cussac2,3,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34750558     DOI： 10.1038/s41591-021-01570-9

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.

Authors:  Binghe Xu; Qingyuan Zhang; Pin Zhang; Xichun Hu; Wei Li; Zhongsheng Tong; Tao Sun; Yuee Teng; Xinhong Wu; Quchang Ouyang; Xi Yan; Jing Cheng; Qiang Liu; Jifeng Feng; Xiaojia Wang; Yongmei Yin; Yanxia Shi; Yueyin Pan; Yongsheng Wang; Weimin Xie; Min Yan; Yunjiang Liu; Ping Yan; Fei Wu; Xiaoyu Zhu; Jianjun Zou
Journal:  Nat Med       Date:  2021-11-04       Impact factor: 87.241
  1 in total
  1 in total

1.  The emerging CDK4/6 inhibitor for breast cancer treatment.

Authors:  M Saeed Sheikh; Siem A Satti
Journal:  Mol Cell Pharmacol       Date:  2021
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.